Targeting the underlying immune mechanism of diabetes-induced myocardial dysfunction via modulation of SIRT-3/p53/TIGAR/PFKFB-3 and SIRT-3/NF-κB signaling pathways as a potential controlling strategy.

The current study explored the potential of methotrexate (MTX) to target type 2 diabetes (T2D)-induced immune response and mitigate the associated myocardial dysfunction, focusing on the modulation of SIRT3-related pathways. T2D was induced in Spragu…

Preview only. Read the full abstract at the source